AEON Biopharma, Inc.

Listed Company

AEONCIK 0001837607NYSEEmerging GrowthPharmaceutical PreparationsDelawareMYFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-39.22M

Total Assets

$5.56M

Equity

$-55.03M

Shares Out

25.30M

Op. Cash Flow

$-17.31M

Business

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a 900 kDa botulinum toxin complex, for therapeutic indications with an initial focus on neuroscience disorders. The company’s core product development activities center on ABP-450 and associated clinical programs, including migraine, cervical dystonia and gastroparesis, supported by preclinical and analytical studies and regulatory engagements. Business activities include licensing, development and commercialization efforts under an exclusive supply and license agreement with Daewoong, which manufactures ABP-450. AEON targets major markets in the United States, Canada, the European Union, the United Kingdom and select international territories through direct commercialization and potential partnerships.

Summary from filing dated 2025-03-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Selling, general and administrative	12	14	14	—
Research and development	4	14	35	—
Change in fair value of contingent consideration	−4	−101	—	—
Total operating costs and expenses	13	−73	48	—
(Loss) income from operations	−13	73	−48	−2
Change in fair value of convertible notes	−23	3	−4	—
Change in fair value of warrants	85	−15	7	11
Loss on issuance of warrants	−76	—	—	—
Loss on embedded forward purchase agreements	—	−20	—	—
Loss on derivative liability	−13	—	—	—
Other income, net	290,000	95,000	289,000	—
Total other loss, net	−26	−31	−4	10
(Loss) income before taxes	−39	42	−53	8
Income taxes	0	0	0	—
Net (loss) income	−39	42	10	8
Basic net (loss) income per share (in dollars per share)	−3.95	77.74	−0.38	—
Diluted net (loss) income per share (in dollars per share)	−3.95	72.93	−0.38	—
Weighted average shares of common stock outstanding used to compute basic net (loss) income per share	10	540,360	139	—
Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share	10	575,945	139	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-07-31	FY 2022 2022-12-31
Cash and cash equivalents	3	13,000	5	31	31
Prepaid expenses and other current assets	392,000	2	1	—	92,000
Total current assets	3	2	6	—	10
Property and equipment, net	162,000	235,000	332,000	—	431,000
Operating lease right-of-use asset	1	1	262,000	—	475,000
Other assets	948,000	29,000	29,000	—	34,000
Total assets	6	3	7	—	11
Accounts payable	942,000	6	3	—	8
Accrued clinical trials expenses	1	4	5	—	2
Accrued compensation	3	1	943,000	—	1
Other accrued expenses	2	4	4	—	740,000
Total current liabilities	7	14	13	—	83
Convertible notes at fair value, including related party amount of $34,600 and $11,689, at December 31, 2025 and 2024, respectively	35	12	—	—	60
Operating lease liability	893,000	1	—	—	242,000
Derivative liability	15	—	—	—	—
Warrant liabilities	3	1	1	—	—
Contingent consideration liability	42,000	4	104	—	—
Total liabilities	61	32	160	—	143
Commitments and contingencies (Note 7)	—	—	—	—	—
Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at December 31, 2025 and 2024, and 12,105,902 and 555,511 shares issued and outstanding at December 31, 2025 and 2024, respectively	9,000	4,000	4,000	—	14,000
Additional paid-in capital	416	403	381	—	187
Accumulated deficit	−471	−432	−474	—	−475
Total stockholders' deficit	−55	−29	−153	−311	−270
Total liabilities and stockholders' deficit	6	3	7	—	11

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net (loss) income	−39	42	−53	8
Depreciation	78,000	97,000	68,000	—
Stock-based compensation expense	5	6	6	—
Non-cash issuance of common stock	250,000	384,000	—	—
Prepaid expenses and other current assets	1	−513,000	−66,000	—
Accounts payable	−5	3	7	—
Accrued expenses and other liabilities	−2	−1	−105,000	—
Other assets and liabilities	−952,000	120,000	−174,000	—
Net cash used in operating activities	−17	−20	−36	−1
Purchases of property and equipment	−4,000	—	−306,000	—
Net cash used in investing activities	−4,000	—	−306,000	−276
Proceeds from issuance of convertible notes	—	15	45	—
Net cash provided by financing activities	20	15	41	278
Net decrease in cash	3	−5	5	497,412
Settlement of liability with common shares	235,000	—	—	—
Cashless warrant exercises	7	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro